CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2012--
Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing
novel therapeutics for autoimmune diseases and vaccine adjuvants, today
announced that members of the management team will be presenting at the
2012 BIO International Convention at the Boston Convention and
Exhibition Center in Boston, MA. The presentation will be made during
the BIO Business forum EST in the Celtics Room (104C) on Wednesday, on
June 20th, 2012 at 10:30am.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates and
has clinical development programs in autoimmune diseases and cancer.
Additionally, Idera has a collaboration with Merck & Co. for the use of
TLR-targeted candidates as vaccine adjuvants. The Company is also
advancing its gene-silencing oligonucleotide (GSO) technology for the
purpose of inhibiting the expression of disease-promoting genes. For
more information, visit http://www.iderapharma.com.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
